NasdaqCM:OPGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally.


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has OpGen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OPGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.5%

OPGN

-1.5%

US Biotechs

3.8%

US Market


1 Year Return

-76.9%

OPGN

22.1%

US Biotechs

9.7%

US Market

Return vs Industry: OPGN underperformed the US Biotechs industry which returned 23.9% over the past year.

Return vs Market: OPGN underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

OPGNIndustryMarket
7 Day0.5%-1.5%3.8%
30 Day-13.3%3.5%11.4%
90 Day-35.9%9.0%6.8%
1 Year-76.9%-76.9%23.3%22.1%12.1%9.7%
3 Year-99.4%-99.4%26.1%22.1%36.2%27.2%
5 Year-99.9%-99.9%-5.5%-11.0%63.7%45.4%

Price Volatility Vs. Market

How volatile is OpGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OpGen undervalued compared to its fair value and its price relative to the market?

1.73x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OPGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OPGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OPGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OPGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OPGN is good value based on its PB Ratio (1.7x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is OpGen forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-16.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OPGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OPGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OPGN's revenue (90.1% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: OPGN's revenue (90.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPGN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OpGen performed over the past 5 years?

3.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OPGN is currently unprofitable.

Growing Profit Margin: OPGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OPGN is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare OPGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: OPGN has a negative Return on Equity (-89.06%), as it is currently unprofitable.


Next Steps

Financial Health

How is OpGen's financial position?


Financial Position Analysis

Short Term Liabilities: OPGN's short term assets ($17.1M) exceed its short term liabilities ($4.9M).

Long Term Liabilities: OPGN's short term assets ($17.1M) exceed its long term liabilities ($768.3K).


Debt to Equity History and Analysis

Debt Level: OPGN's debt to equity ratio (3.6%) is considered satisfactory.

Reducing Debt: OPGN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OPGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OPGN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 3.3% each year


Next Steps

Dividend

What is OpGen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OPGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.2yrs

Average management tenure


CEO

Oliver Schacht (48yo)

0.17

Tenure

Dr. Oliver Schacht, Ph.D., serves as Director, President and Chief Executive Officer at OpGen, Inc. since April 1, 2020. He was the Member of Management Board at Curetis N.V. since April 2011 and served as ...


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Dec
CFO & Corporate Secretary5.17yrsUS$315.47k0.0061% $1.8k
Vadim Sapiro
Chief Information Officer8.5yrsUS$311.05k0.0010% $293.9
Oliver Schacht
CEO, President & Director0.17yrno datano data
Johannes Bacher
Chief Operating Officer0.17yrno datano data
Michael Farmer
Vice President of Marketingno datano datano data
Faranak Atrzadeh
Chief Marketing & Scientific Affairs Officer0.17yrno datano data
G. Walker
Senior Vice President of Research & Development5.67yrsno datano data
Christopher Emery
Chief Commercial Officer for the Americas0.17yrno datano data
Andreas Posch
CEO of Ares Genetics GmbH0.17yrno datano data

0.2yrs

Average Tenure

50yo

Average Age

Experienced Management: OPGN's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Oliver Schacht
CEO, President & Director0.17yrno datano data
William Rhodes
Independent Chairman0.17yrno datano data
Evan Jones
Directorno dataUS$448.43k0.0017% $511.3
Attila Lorincz
Member of Clinical Advisory Boardno datano datano data
R. Elsey
Independent Director1.33yrsUS$48.93kno data
James Snyder
Member of Clinical Advisory Boardno datano datano data
Debra Goff
Member of Clinical Advisory Board4.25yrsno datano data
Stefan Riedel
Member of Clinical Advisory Board4.25yrsno datano data
Morton Sommer
Member of Clinical Advisory Board4.25yrsno datano data
Patricia Simner
Member of Clinical Advisory Boardno datano datano data

2.8yrs

Average Tenure

64yo

Average Age

Experienced Board: OPGN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1608.1%.


Top Shareholders

Company Information

OpGen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OpGen, Inc.
  • Ticker: OPGN
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$29.387m
  • Shares outstanding: 15.07m
  • Website: https://www.opgen.com

Number of Employees


Location

  • OpGen, Inc.
  • 708 Quince Orchard Road
  • Suite 205
  • Gaithersburg
  • Maryland
  • 20878
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OPGNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2015
6502DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2015

Biography

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company’s products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 07:17
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.